Navigation Links
Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
Date:7/3/2008

NAPA, Calif., July 3 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced termination of the Invicorp(R) License Agreement with Ardana Bioscience Limited ("Ardana"). The Agreement was a license to manufacture, market, sell and distribute Invicorp(R) in Europe and was terminated pursuant to the Company's contractual rights, precipitated by Ardana's entry into voluntary administration on June 27, 2008.

Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer stated, "We have advised Ardana of the Invicorp(R) License termination and served demand for return of all related clinical and regulatory data. We have received a number of inquiries regarding the availability of the European license and we are confident this will be a valuable and productive asset in the hands of the right partner".

Invicorp(R), is a highly safe and effective treatment for erectile dysfunction ("ED"), a condition that affects more than 100 million men worldwide. Invicorp(R) is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line ED treatment. Invicorp(R) has received marketing authorization in Denmark as well as in England. Additionally, Invicorp(R) has been approved in New Zealand. Senetek has entered into an exclusive licensing and collaborative marketing agreement for the commercialization of Invicorp(R) with Plethora Solutions for the North American market.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
2. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
3. Senetek PLC Announces Key Personnel Appointments
4. Senetek PLC Reports 2007 Financial Results
5. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
6. Senetek PLC Announces Launch of New Website
7. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
8. Senetek PLC Reports Third Quarter 2007 Financial Results
9. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
10. Hooper Holmes Announces Sale of Claims Evaluation Division
11. Transition Therapeutics Announces Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Lewisville, TX (PRWEB) , ... July 24, 2017 ... ... grants under the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State ... State of California Department of Health Care Services, will facilitate the development of ...
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... to expand its solution to help government contractors more quickly and cost-effectively comply ... to address the authentication requirements within NIST SP800-171, but no matter how you ...
(Date:7/24/2017)... ... ... people are taking more steps to protect themselves from sunburn, half of all adults and ... the past year. It’s common and people have been dealing with them since the dawn ... conscientious of the risks that accompany sunburns. , The team at AloeVera.com , a ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... August 13-17 in National Harbor, MD. This year's theme focuses on the new ... principal benchmarks for quality and integrity in testing and calibration will be changed. ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: